Abdominal aBscess Catheter Sclerotherapy (ABCS)

Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Mar 28, 2025

Keywords

ClinConnect Summary

The Abdominal aBscess Catheter Sclerotherapy (ABCS) trial is a research study aimed at helping patients with abdominal abscesses, which are pockets of infection in the belly. This trial will test two different substances, ethanol and povidone iodine, to see if they can help reduce the time patients need to keep a drainage catheter in place. The study will involve around 60 participants, split into two groups, and is focused on patients 18 years and older who have an abscess measuring at least 3 centimeters in size.

To be eligible for this trial, participants must be generally healthy, free from certain allergies, and not pregnant or breastfeeding. Those who join the study will closely monitor how well they tolerate the treatments and whether they need to have their drainage catheter replaced within a week after the procedure. It’s important for potential participants to be willing to follow all study guidelines and to be available throughout the duration of the trial. The study is not yet recruiting participants, but it aims to provide valuable information that could improve treatment for abdominal abscesses in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female, aged over 18years
• • Cross-sectional imaging (CT, US, MRI) showing an intraabdominal abscess measuring at last 3cm in each dimension without fistula to the bowel or skin.
• • Provision of signed and dated informed consent form
• • Stated willingness to comply with all study procedures and availability for the duration of the study
• Exclusion Criteria:
• • Pregnancy or lactation
• • Known allergic reactions to povidone iodine or ethanol
• • Hemodynamic instability